---
schema_version: "secwatch.filing_event.v1"
accession: "0001808805-22-000003"
form_type: "8-K"
ticker: "NAUT"
cik: "0001808805"
company_name: "Nautilus Biotechnology, Inc."
filed_at: "2022-02-24T23:59:59+00:00"
generated_at: "2026-06-27T04:59:39.831252+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nautilus Biotechnology reports FY2021 net loss of $50.3M; operating expenses up 221% to $50.5M

## Summary
- FY2021 net loss $50.3M, compared to $15.6M in 2020; operating expenses $50.5M, up 221%.
- Cash, equivalents, investments $362.1M as of Dec 31, 2021; raised ~$345.5M via SPAC merger in June 2021.
- Research collaborations with Amgen and MD Anderson; strategic partnership with Abcam for reagents.
- Platform commercialization targeted by end of 2023; published PrISM proteomics approach.

## SEC filing metadata
- accession: 0001808805-22-000003
- form_type: 8-K
- ticker: NAUT
- cik: 0001808805
- company_name: Nautilus Biotechnology, Inc.
- filed_at: 2022-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808805/000180880522000003/0001808805-22-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808805/000180880522000003/naut-20220224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001808805-22-000003
- JSON: https://secwatch.observer/filing/0001808805-22-000003.json
- Plain text: https://secwatch.observer/filing/0001808805-22-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.